Reviewing Eterna Therapeutics (NASDAQ:ERNA) & China Dongsheng International (OTCMKTS:CDSG)

Volatility & Risk

Eterna Therapeutics has a beta of 4.41, meaning that its share price is 341% more volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 15.42, meaning that its share price is 1,442% more volatile than the S&P 500.

Profitability

This table compares Eterna Therapeutics and China Dongsheng International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eterna Therapeutics -7,513.88% -1,466.71% -117.48%
China Dongsheng International N/A N/A N/A

Institutional & Insider Ownership

70.6% of Eterna Therapeutics shares are held by institutional investors. 4.5% of Eterna Therapeutics shares are held by insiders. Comparatively, 73.5% of China Dongsheng International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Eterna Therapeutics and China Dongsheng International”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eterna Therapeutics $70,000.00 73.19 -$21.67 million ($8.31) -0.11
China Dongsheng International N/A N/A -$100,000.00 N/A N/A

China Dongsheng International has lower revenue, but higher earnings than Eterna Therapeutics.

Summary

China Dongsheng International beats Eterna Therapeutics on 6 of the 8 factors compared between the two stocks.

About Eterna Therapeutics

(Get Free Report)

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About China Dongsheng International

(Get Free Report)

China Dongsheng International, Inc. engages in the acquisition, exploration, and development of mineral properties. The company primarily explores for lithium. It holds an 80% interest in the Titan Projects located in Tanzania; and has right to earn 60% interest in the West End Lithium Project near Tonopah Nevada. China Dongsheng International, Inc. is based in Las Vegas, Nevada.

Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.